Skip to main content
Addgene

pCAG-p21_T145A/S146A
(Plasmid #42623)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 42623 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pCAG
  • Backbone manufacturer
    Invivogen
  • Modifications to backbone
    Modified backbone from pDRIVE-CAG.
  • Vector type
    Mammalian Expression
  • Selectable markers
    no selectable marker

Growth in Bacteria

  • Bacterial Resistance(s)
    Bleocin (Zeocin), 50 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    p21
  • Alt name
    WAF1
  • Alt name
    Cip1
  • Species
    H. sapiens (human)
  • Mutation
    T145A/S146A
  • Entrez Gene
    CDKN1A (a.k.a. CAP20, CDKN1, CIP1, MDA-6, P21, SDI1, WAF1, p21CIP1)
  • Promoter CAG

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site EcoRI (unknown if destroyed)
  • 3′ cloning site BamHI (unknown if destroyed)
  • 5′ sequencing primer NA
  • 3′ sequencing primer NA
  • (Common Sequencing Primers)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pCAG-p21_T145A/S146A was a gift from Philipp Mergenthaler (Addgene plasmid # 42623 ; http://n2t.net/addgene:42623 ; RRID:Addgene_42623)
  • For your References section:

    A functional role of the cyclin-dependent kinase inhibitor 1 (p21(WAF1/CIP1)) for neuronal preconditioning. Mergenthaler P, Muselmann C, Sunwoldt J, Isaev NK, Wieloch T, Dirnagl U, Meisel A, Ruscher K. J Cereb Blood Flow Metab. 2013 Mar;33(3):351-5. doi: 10.1038/jcbfm.2012.213. Epub 2013 Jan 9. 10.1038/jcbfm.2012.213 PubMed 23299246